AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18824462 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin and 10 mg ezetimibe combination therapy
Number of subjects: 0
Study 18824462 — intervention group
Group type: COMPARATOR
Intervention: Non-obese healthy controls
Number of subjects: 0
Study 18824462 — intervention group
Group type: COMPARATOR
Intervention: Obese men with metabolic syndrome (baseline)
Number of subjects: 0
Study 16000605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based adjuvant chemotherapy
Number of subjects: 1394
Study 16000605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (platinum-based)
Number of subjects: 1394
Study 12794583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nifedipine
Number of subjects: 52
Study 12794583 — intervention group
Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate
Number of subjects: 52
Study 12794583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 52
Study 9927017 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (5.03 g CHO x kg BM(‐1))
Number of subjects: 12
Study 9927017 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet (3.89 g CHO x kg BM(‐1))
Number of subjects: 12
Study 9927017 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 12
Study 9927017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid-threshold (LAT) exercise
Number of subjects: 12
Study 9927017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid-threshold -20 (LAT-20) exercise
Number of subjects: 12
Study 9927017 — intervention group
Group type: COMPARATOR
Intervention: Control (nonexercise session)
Number of subjects: 12
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: M-PLA2
Number of subjects: 184
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: PMN-E
Number of subjects: 184
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 184
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: u-PA
Number of subjects: 184
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1
Number of subjects: 184
Study 7778023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of M-PLA2, PMN-E, and t-PA
Number of subjects: 184
Study 2361776 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ion condition
Number of subjects: 73
Study 2361776 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 73
Study 155891 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microgram ipratropium
Number of subjects: 21
Study 155891 — intervention group
Group type: COMPARATOR
Intervention: 200 microgram salbutamol
Number of subjects: 21
Study 155891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and salbutamol
Number of subjects: 21
Study 31734334 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily GSP301 (olopatadine 665 μg and mometasone 25 μg)
Number of subjects: 1111
Study 31734334 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily GSP301 (olopatadine 665 μg and mometasone 50 μg)
Number of subjects: 1111
Study 31734334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 31734334 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily olopatadine (665 μg)
Number of subjects: 1111
Study 31734334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone monotherapy (twice-daily 25 μg or once-daily 50 μg)
Number of subjects: 1111
Study 31734334 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily mometasone
Number of subjects: 1111
Study 30528849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (carbohydrates, proteins, electrolytes, osmolarity of 680 mO.L‐1, 300 kcal)
Number of subjects: 34
Study 30528849 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic solution (carbohydrates, electrolytes, osmolarity of 292 mOsm.L‐1, 36 kcal)
Number of subjects: 34
Study 30528849 — intervention group
Group type: COMPARATOR
Intervention: Fasting (control group)
Number of subjects: 34
Study 30528849 — intervention group
Group type: COMPARATOR
Intervention: Comparison between isotonic solution and nutritional supplementation
Number of subjects: 34
Study 30067065 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 63
Study 30067065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rope skipping
Number of subjects: 63
Study 30067065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 63
Study 30067065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 63
Study 30067065 — intervention group
Group type: COMPARATOR
Intervention: Older population (40-55 years) vs. younger population (18-25 years)
Number of subjects: 63
Study 30067065 — intervention group
Group type: COMPARATOR
Intervention: Older male participants vs. older female participants
Number of subjects: 63
Study 27608621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based lifestyle program (6-week duration)
Number of subjects: 35
Study 27608621 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 35
Study 24507377 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA401 (100 mg twice daily)
Number of subjects: 183
Study 24507377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized presentation of immediate rewards
Number of subjects: 9454
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending presentation of immediate rewards
Number of subjects: 9454
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending presentation of immediate rewards
Number of subjects: 9454
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays between 1 week and 5 years with delayed amounts of $1000 and $100 for 1 month
Number of subjects: 9454
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbolic DRD function
Number of subjects: 9454
Study 22126134 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodology variations (randomized order, longer delays, smaller rewards)
Number of subjects: 9454
Study 19443189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with purified air
Number of subjects: 22
Study 19443189 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with unfiltered air
Number of subjects: 22
Study 17192489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day) and Fenofibrate (160 mg/day)
Number of subjects: 8
Study 15113785 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular feedback to primary care providers of synthesized information on patients' health, function, and satisfaction.
Number of subjects: 0
Study 15113785 — intervention group
Group type: COMPARATOR
Intervention: Control firms (no feedback provided).
Number of subjects: 0
Study 11245863 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care management (EG)
Number of subjects: 250
Study 11245863 — intervention group
Group type: COMPARATOR
Intervention: Hospital care management (CG)
Number of subjects: 250
Study 9555866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with palmitic acid (21.7 g)
Number of subjects: 91
Study 9555866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with stearic acid (18.6 g)
Number of subjects: 91
Study 9555866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with linoleic/linolenic acid (ratio 3:1)
Number of subjects: 91
Study 9555866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich breakfast with linoleic/linolenic acid (ratio 15:1)
Number of subjects: 91
Study 9555866 — intervention group
Group type: COMPARATOR
Intervention: Control breakfast (1.5 en% fat)
Number of subjects: 91
Study 9555866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich breakfasts (all types)
Number of subjects: 91
Study 8053586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (target temperature 35 degrees C, allowed to drift to 34.5 degrees C before rewarming)
Number of subjects: 30
Study 8053586 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (target temperature 36.5-37.0 degrees C)
Number of subjects: 30
Study 8053586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 30
Study 3419245 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 8
Study 3419245 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (2 mg)
Number of subjects: 8
Study 3419245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (20 mg)
Number of subjects: 8
Study 3419245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3419245 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg and 2 mg)
Number of subjects: 8
Study 29354936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake-separated moxibustion
Number of subjects: 90
Study 29354936 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 90
Study 29354936 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study 26597705 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA-FS
Number of subjects: 786
Study 26597705 — intervention group
Group type: COMPARATOR
Intervention: CF
Number of subjects: 786
Study 25273077 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 92
Study 25273077 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 in combination with leucovorin (SL)
Number of subjects: 92
Study 22207279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 68
Study 20228415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor
Number of subjects: 103
Study 20228415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 18028881 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 14
Study 18028881 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated volunteers)
Number of subjects: 14
Study 15681102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral immunonutrition (formula supplemented with arginine, omega‐3 fatty acids and RNA)
Number of subjects: 66
Study 15681102 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric‐isonitrogenous control formula
Number of subjects: 66
Study 12658934 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 60
Study 12658934 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 60
Study 12658934 — intervention group
Group type: COMPARATOR
Intervention: CSEA
Number of subjects: 60
Study 12658934 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 60
Study 8841865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (5 micrograms/mL)
Number of subjects: 40
Study 8841865 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 40
Study 8841865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine with and without epinephrine)
Number of subjects: 40
Study 8841865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 40
Study 2253572 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO‐MDT
Number of subjects: 127
Study 2253572 — intervention group
Group type: COMPARATOR
Intervention: Modified‐MDT
Number of subjects: 127
Study 6254457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 13
Study 6254457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30601161 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Giapreza)
Number of subjects: 0
Study 30601161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 84
Study 27180065 — intervention group
Group type: COMPARATOR
Intervention: Body fat percentage (BF%)
Number of subjects: 84
Study 26062189 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurphen mixture (droperidol injection 1.25 mg and fentanyl citrate injection 0.05 mg diluted to 6 mL with 0.9% sodium chloride solution 4.5 mL) injected at bilateral Shenshu (BL 23) 15 to 20 min before ESWL.
Number of subjects: 64
Study 26062189 — intervention group
Group type: COMPARATOR
Intervention: Control group with no adjuvant therapy or medication before ESWL.
Number of subjects: 64
Study 23199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of change in white bread intake
Number of subjects: 2213
Study 22151934 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐ascorbic acid 10% + phytic acid 2%
Number of subjects: 30
Study 22151934 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study 19430833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 64
Study 19430833 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoloop and hemoclip application
Number of subjects: 64
Study 17561127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic local anesthesia with 2 ml 1% lidocaine and periprostatic injection of 2 ml saline (Group 1)
Number of subjects: 152
Study 17561127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of 2 ml saline followed by periprostatic local anesthesia with 2 ml 1% lidocaine (Group 2)
Number of subjects: 152
Study 17561127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic and periprostatic local anesthesia with 2 ml 1% lidocaine (Group 3)
Number of subjects: 152
Study 17561127 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 152
Study 15334503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis children with meconium ileus (MI)
Number of subjects: 32
Study 15334503 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis children without meconium ileus (control group)
Number of subjects: 32
Study 11158797 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (n = 127)
Number of subjects: 369
Study 11158797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116)
Number of subjects: 369
Study 11158797 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (n = 126)
Number of subjects: 369
Study 10495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical psychotherapy data
Number of subjects: 0
Study 10495194 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational study data
Number of subjects: 0
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed diabetes
Number of subjects: 1008
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 1008
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1008
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 1008
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked obesity (BMI 30 kg/m2 or more)
Number of subjects: 1008
Study 7481176 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed diabetic patients
Number of subjects: 1008
Study 1973905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral dose of gepirone
Number of subjects: 14
Study 1973905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1973905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg gepirone (acute administration)
Number of subjects: 14
Study 1973905 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of gepirone (3-6 weeks)
Number of subjects: 14
Study 13090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisotropine methylbromide (high doses)
Number of subjects: 0
Study 31278508 — intervention group
Group type: EXPERIMENTAL
Intervention: Joline RapidIntro Vertebra Access Device with a trocar tip
Number of subjects: 65
Study 31278508 — intervention group
Group type: EXPERIMENTAL
Intervention: Joline SpeedTrack Vertebra Introducer Device with a short, tapered tip
Number of subjects: 65
Study 31278508 — intervention group
Group type: COMPARATOR
Intervention: Joline Vertebra Access Device (control)
Number of subjects: 65
Study 28794060 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary community-based obesity programme
Number of subjects: 233
Study 25912051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (IV) administered as multiple 30- or 15-min infusions every 6 h, and as a single rapid infusion
Number of subjects: 203
Study 25912051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (IV) administered as rapid infusions
Number of subjects: 203
Study 25912051 — intervention group
Group type: COMPARATOR
Intervention: Oral carbamazepine
Number of subjects: 203
Study 24018675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparassis crispa (SC)
Number of subjects: 0
Study 24018675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21846343 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids supplement
Number of subjects: 0
Study 21846343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given omega-3 supplements)
Number of subjects: 0
Study 19214137 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐10 (8 microg/kg)
Number of subjects: 305
Study 19214137 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐10 (20 microg/kg)
Number of subjects: 305
Study 19214137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 17437662 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers of type II collagen
Number of subjects: 0
Study 17437662 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassays detecting fragments of aggrecan
Number of subjects: 0
Study 17437662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of different biochemical markers
Number of subjects: 0
Study 15156527 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 15156527 — intervention group
Group type: EXPERIMENTAL
Intervention: ARBs
Number of subjects: 0
Study 15156527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ACE inhibitor-ARB therapy
Number of subjects: 0
Study 15156527 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors and ARBs (combined)
Number of subjects: 0
Study 15156527 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (from trials)
Number of subjects: 0
Study 15156527 — intervention group
Group type: COMPARATOR
Intervention: ARBs (from trials)
Number of subjects: 0
Study 11699048 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP2 Thr/Thr genotype in older normoglycemic men
Number of subjects: 504
Study 11699048 — intervention group
Group type: EXPERIMENTAL
Intervention: beta3AR Arg64-positive subjects in older normoglycemic men
Number of subjects: 504
Study 11699048 — intervention group
Group type: EXPERIMENTAL
Intervention: beta3AR Arg64-positive group in older hyperglycemic men
Number of subjects: 504
Study 9542852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute scrub with povidone-iodine followed by alcohol foam
Number of subjects: 37
Study 9542852 — intervention group
Group type: COMPARATOR
Intervention: 5-minute scrub with povidone-iodine
Number of subjects: 37
Study 10168562 — intervention group
Group type: EXPERIMENTAL
Intervention: Excel cell separator
Number of subjects: 25
Study 10168562 — intervention group
Group type: EXPERIMENTAL
Intervention: MCS 3p cell separator
Number of subjects: 25
Study 10168562 — intervention group
Group type: COMPARATOR
Intervention: CS3000 plus, AS 104, Cobe Spectra
Number of subjects: 25
Study 2689236 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 115
Study 2689236 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with short-term (ST) 5-FU (575 mg/m2 daily for 4 days before irradiation)
Number of subjects: 115
Study 2689236 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with long-term (LT) 5-FU (750 mg/m2 every 2 weeks for 18 months)
Number of subjects: 115
Study 2689236 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with both ST and LT 5-FU
Number of subjects: 115
Study 2689236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with ST and LT 5-FU
Number of subjects: 115
Study 30974973 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (degludec) using FlexTouch1
Number of subjects: 145
Study 28152999 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 186
Study 28152999 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 26248094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 26248094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23760870 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid 10 %/flumethrin 4.5 % polymer matrix collar (Seresto®, Bayer)
Number of subjects: 16
Study 23760870 — intervention group
Group type: COMPARATOR
Intervention: Placebo collar
Number of subjects: 16
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of diabetic retinopathy
Number of subjects: 1211
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of diabetic retinopathy
Number of subjects: 1211
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) associated with incident diabetic retinopathy
Number of subjects: 1211
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes associated with incident diabetic retinopathy
Number of subjects: 1211
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure associated with incident diabetic retinopathy
Number of subjects: 1211
Study 21630126 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index associated with incident diabetic retinopathy
Number of subjects: 1211